The first person has received Moderna’s COVID-19 vaccine booster that targets the Omicron virus variant, the company announced Wednesday. The Phase 2 study is expected to enroll approximately 600 adults 18 or older, half of whom have received two doses of Moderna’s original vaccine and half of whom have received both the primary two-dose series and a booster that doesn’t target Omicron. Both cohorts will receive a single additional shot that’s aimed at Omicron, a variant of the CCP (Chinese Communist Party) virus that became dominant in the United States last month. The CCP virus causes COVID-19. It wasn’t clear where the trial will take place and a Moderna spokeswoman didn’t immediately return emailed questions. The announcement came hours after scientists with Moderna, the National Institutes of Health, and other institutions had a study published in the New England Journal of Medicine that found Moderna’s original regimen elicited 25 times fewer neutralizing antibodies against …